Loading…
Reported covered position: Thomas J. Bliley, Jr. (1991)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Lower Costs, More Cures Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Coronavirus- COVID-19; issues related to Influenza Vaccines; issues related to prescription medicines switch to over-the-counter; and other general issues related to routine influenza rates; issues related to 340B; issues related to drug importation, issues related to international reference pricing; issues related to Most Favored Nation Executive Order; issues related to Executive Order on Flu Vaccines; issues related to HR3. "Lower Drug Cost Now act of 2019; general issues related to drug pricing; issues related to HHS Rebate Rule; issues related to insulin pricing; issues related to compulsory licensing; issues related to S.3548 "CARES Act"; and issues related to HR19 "Lower Costs, More Cures Act of 2019".
Elijah E. Cummings Lower Drug Costs Now Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2020 · fourth_quarter · Q4
General issues related to supply chain.
Issues related to Coronavirus- COVID-19; issues related to Influenza Vaccines; issues related to prescription medicines switch to over-the-counter; and other general issues related to routine influenza rates; issues related to 340B; issues related to drug importation, issues related to international reference pricing; issues related to Most Favored Nation Executive Order; issues related to Executive Order on Flu Vaccines; issues related to HR3. "Lower Drug Cost Now act of 2019; general issues related to drug pricing; issues related to HHS Rebate Rule; issues related to insulin pricing; issues related to compulsory licensing; issues related to S.3548 "CARES Act"; and issues related to HR19 "Lower Costs, More Cures Act of 2019".
Source: Senate LDA
general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform in CARES Act; issues related to HSA/FSA in CARES Act; issues related to Vaccine provisions in CARES Act; issues related to prescription to over-the-counter switch; issues related to Drug Importation;issues related to H.R. 3 "Lower Drug Costs Now Act of 2019"; issues related to S. 2740 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019"; issues related to influenza vaccines; issues related to the Executive Order on Flu; issues related to Coronavirus COVID-19; issues related to Copay Accumulators; issues related to RSV access; issues related to HR.3433- Over the counter Monograph Safety, Innovation and Reform Act 2019; issues related to S.2158- Newborn Screening Saves Lives; and issues related to CMMI- Insulin Demo.
Elijah E. Cummings Lower Drug Costs Now Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Coronavirus- COVID-19; issues related to Influenza Vaccines; issues related to prescription medicines switch to over-the-counter; and other general issues related to routine influenza rates; issues related to 340B; issues related to drug importation, issues related to international reference pricing; issues related to Most Favored Nation Executive Order; issues related to Executive Order on Flu Vaccines; issues related to HR3. "Lower Drug Cost Now act of 2019; general issues related to drug pricing; issues related to HHS Rebate Rule; issues related to insulin pricing; issues related to compulsory licensing; issues related to S.3548 "CARES Act"; and issues related to HR19 "Lower Costs, More Cures Act of 2019".
Elijah E. Cummings Lower Drug Costs Now Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Coronavirus- COVID-19; issues related to Influenza Vaccines; issues related to prescription medicines switch to over-the-counter; and other general issues related to routine influenza rates; issues related to 340B; issues related to cosmetic regulations; issues related to drug importation, issues related to international reference pricing; issues related to Most Favored Nation Executive Order; issues related to OTC monograph reform; issues related to Executive Order on Flu Vaccines; issues related to CMMI Insulin demo; issues related to copay accumulators; and issues related to HR3. "Lower Drug Cost Now act of 2019".
ASC Payment Transparency Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform in CARES Act; issues related to HSA/FSA in CARES Act; issues related to Vaccine provisions in CARES Act; issues related to prescription to over-the-counter switch; issues related to Drug Importation;issues related to H.R. 3 "Lower Drug Costs Now Act of 2019"; issues related to S. 2740 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019"; issues related to influenza vaccines; issues related to the Executive Order on Flu; issues related to Coronavirus COVID-19; issues related to Copay Accumulators; issues related to RSV access; issues related to HR.3433- Over the counter Monograph Safety, Innovation and Reform Act 2019; issues related to S.2158- Newborn Screening Saves Lives; and issues related to CMMI- Insulin Demo.
Prescription Drug Price Relief Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform in CARES Act; issues related to HSA/FSA in CARES Act; issues related to Vaccine provisions in CARES Act; issues related to prescription to over-the-counter switch; issues related to Drug Importation;issues related to H.R. 3 "Lower Drug Costs Now Act of 2019"; issues related to S. 2740 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019"; issues related to influenza vaccines; issues related to the Executive Order on Flu; issues related to Coronavirus COVID-19; issues related to Copay Accumulators; issues related to RSV access; issues related to HR.3433- Over the counter Monograph Safety, Innovation and Reform Act 2019; issues related to S.2158- Newborn Screening Saves Lives; and issues related to CMMI- Insulin Demo.
Vaccine Access Improvement Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Tax Reform; and issues S.1654- Vaccine Access Improvement Act of 2019.
The Newborn Screening Saves Lives Reauthorization Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform in CARES Act; issues related to HSA/FSA in CARES Act; issues related to Vaccine provisions in CARES Act; issues related to prescription to over-the-counter switch; issues related to Drug Importation;issues related to H.R. 3 "Lower Drug Costs Now Act of 2019"; issues related to S. 2740 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019"; issues related to influenza vaccines; issues related to the Executive Order on Flu; issues related to Coronavirus COVID-19; issues related to Copay Accumulators; issues related to RSV access; issues related to HR.3433- Over the counter Monograph Safety, Innovation and Reform Act 2019; issues related to S.2158- Newborn Screening Saves Lives; and issues related to CMMI- Insulin Demo.
Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform in CARES Act; issues related to HSA/FSA in CARES Act; issues related to Vaccine provisions in CARES Act; issues related to prescription to over-the-counter switch; issues related to Drug Importation;issues related to H.R. 3 "Lower Drug Costs Now Act of 2019"; issues related to S. 2740 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019"; issues related to influenza vaccines; issues related to the Executive Order on Flu; issues related to Coronavirus COVID-19; issues related to Copay Accumulators; issues related to RSV access; issues related to HR.3433- Over the counter Monograph Safety, Innovation and Reform Act 2019; issues related to S.2158- Newborn Screening Saves Lives; and issues related to CMMI- Insulin Demo.
Issues related to Coronavirus- COVID-19; issues related to Influenza Vaccines; issues related to prescription medicines switch to over-the-counter; and other general issues related to routine influenza rates; issues related to 340B; issues related to drug importation, issues related to international reference pricing; issues related to Most Favored Nation Executive Order; issues related to Executive Order on Flu Vaccines; issues related to HR3. "Lower Drug Cost Now act of 2019; general issues related to drug pricing; issues related to HHS Rebate Rule; issues related to insulin pricing; issues related to compulsory licensing; issues related to S.3548 "CARES Act"; and issues related to HR19 "Lower Costs, More Cures Act of 2019".
National Defense Authorization Act for Fiscal Year 2021
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to BARDA/Biodefense appropriations; and issues related to S.4049 NDAA for FY 2021.
Lower Costs, More Cures Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to prescription to over-the-counter switch; issues related to compulsory licensing; issues related to Drug Importation;issues related to H.R. 3 "Lower Drug Costs Now Act of 2019"; issues related to S. 2740 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019"; issues related to influenza vaccines; issues related to the Executive Order on Flu; and issues related to H.R. 19 "Lower Costs, More Cures Act of 2019" .
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing; issues related to seasonal influenza vaccination; issues related to Drug Importation;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to Arbitration; issues related to H.R. 2087 "Drug Price Transparency Act"; issues related to S.977 "Medicare Drug Price Negotiation Act"; issues related to S.1379 " Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019"; and issues related to H.R. 269 "Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019:.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing; issues related to seasonal influenza vaccination; issues related to Drug Importation; issues related to S. 97 " Affordable and Safe Prescription Drug Importation Act"; issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to dietary supplements; and issues related to H.R. 269 "Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019:.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing; issues related to seasonal influenza vaccination; issues related to Drug Importation;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to Arbitration; issues related to H.R. 2087 "Drug Price Transparency Act"; issues related to S.977 "Medicare Drug Price Negotiation Act"; issues related to S.1379 " Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019"; and issues related to H.R. 269 "Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019:.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to Arbitration;; issues related to S.1379 " Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019"; issues related to H.R. 269 "Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019; issues related to prescription to over-the-counter switch; issues related to compulsory licensing; issues related to Drug Importation; and issues related to H.R. 3 "Lower Drug Costs Now Act of 2019".
Elijah E. Cummings Lower Drug Costs Now Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to Arbitration;; issues related to S.1379 " Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019"; issues related to H.R. 269 "Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019; issues related to prescription to over-the-counter switch; issues related to compulsory licensing; issues related to Drug Importation; and issues related to H.R. 3 "Lower Drug Costs Now Act of 2019".
Elijah E. Cummings Lower Drug Costs Now Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to prescription to over-the-counter switch; issues related to compulsory licensing; issues related to Drug Importation;issues related to H.R. 3 "Lower Drug Costs Now Act of 2019"; issues related to S. 2740 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019"; issues related to influenza vaccines; issues related to the Executive Order on Flu; and issues related to H.R. 19 "Lower Costs, More Cures Act of 2019" .
Issues related to S.340 "CREATES Act of 2019"; and issues related to HR 3199 "Terminating the Extension of Rights Misappropriated Act of 2019"
Prescription Drug Price Relief Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing; issues related to seasonal influenza vaccination; issues related to Drug Importation;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to Arbitration; issues related to H.R. 2087 "Drug Price Transparency Act"; issues related to S.977 "Medicare Drug Price Negotiation Act"; issues related to S.1379 " Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019"; and issues related to H.R. 269 "Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019:.
Prescription Drug Price Relief Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to Arbitration;; issues related to S.1379 " Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019"; issues related to H.R. 269 "Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019; issues related to prescription to over-the-counter switch; issues related to compulsory licensing; issues related to Drug Importation; and issues related to H.R. 3 "Lower Drug Costs Now Act of 2019".
Prescription Drug Price Relief Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to prescription to over-the-counter switch; issues related to compulsory licensing; issues related to Drug Importation;issues related to H.R. 3 "Lower Drug Costs Now Act of 2019"; issues related to S. 2740 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019"; issues related to influenza vaccines; issues related to the Executive Order on Flu; and issues related to H.R. 19 "Lower Costs, More Cures Act of 2019" .
Prescription Drug Price Relief Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing; issues related to seasonal influenza vaccination; issues related to Drug Importation; issues related to S. 97 " Affordable and Safe Prescription Drug Importation Act"; issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to dietary supplements; and issues related to H.R. 269 "Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019:.
Restoring Access to Medication Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
S.1089 "Restoring Access to Medication Act of 2019" provision to repeal tax provisions to prevent HSA eligibility for OTC medicines.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to Arbitration;; issues related to S.1379 " Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019"; issues related to H.R. 269 "Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019; issues related to prescription to over-the-counter switch; issues related to compulsory licensing; issues related to Drug Importation; and issues related to H.R. 3 "Lower Drug Costs Now Act of 2019".
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing; issues related to seasonal influenza vaccination; issues related to Drug Importation;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to Arbitration; issues related to H.R. 2087 "Drug Price Transparency Act"; issues related to S.977 "Medicare Drug Price Negotiation Act"; issues related to S.1379 " Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019"; and issues related to H.R. 269 "Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019:.
Affordable Prescriptions for Patients Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Compulsory Licensing; issues related to drug patents; and issues related to S. 1416 "Affordable Prescription for Patients Act of 2019".
Issues related to Compulsory Licensing; issues related to drug patents; and issues related to S. 2082 "Support Technology and Research for Our Nation's Growth and Economic Resilience Patents Act of 2019".
Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to prescription to over-the-counter switch; issues related to compulsory licensing; issues related to Drug Importation;issues related to H.R. 3 "Lower Drug Costs Now Act of 2019"; issues related to S. 2740 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019"; issues related to influenza vaccines; issues related to the Executive Order on Flu; and issues related to H.R. 19 "Lower Costs, More Cures Act of 2019" .
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.340 "CREATES Act of 2019".
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.340 "CREATES Act of 2019"; and issues related to HR 3199 "Terminating the Extension of Rights Misappropriated Act of 2019"
Hatch-Waxman Integrity Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Compulsory Licensing; issues related to drug patents; and issues related to S.344 "Hatch-Waxman Integrity Act of 2019".
Affordable and Safe Prescription Drug Importation Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing; issues related to seasonal influenza vaccination; issues related to Drug Importation; issues related to S. 97 " Affordable and Safe Prescription Drug Importation Act"; issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to dietary supplements; and issues related to H.R. 269 "Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019:.
Transparent Drug Pricing Act of 2019
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing; issues related to seasonal influenza vaccination; issues related to Drug Importation;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to Arbitration; issues related to H.R. 2087 "Drug Price Transparency Act"; issues related to S.977 "Medicare Drug Price Negotiation Act"; issues related to S.1379 " Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019"; and issues related to H.R. 269 "Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019:.
Medicare Drug Price Negotiation Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.99 "Medicare Drug Price Negotiation Act"
Medicare Drug Price Negotiation Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.99 "Medicare Drug Price Negotiation Act"; issues related to blended ASP authorized generics; issues related to Medicaid AMP CAP; and issues related to international price index.
Medicare Drug Price Negotiation Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to blended ASP authorized generics; issues related to Medicaid AMP CAP; issues related to S.99 "Medicare Drug Price Negotiation Act"; and issues related to Medicare Part D.
Consolidated Appropriations Act, 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to HR1625 "Consolidated Appropriations Act of 2018"; issues related to HR1892 "Bipartisan Budget Act of 2018"; issues related to National Institute of Health (NIH) funding; and issues related to Biomedical Advanced Research and Development Authority (BARDA)".
Bipartisan Budget Act of 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to HR1625 "Consolidated Appropriations Act of 2018"; issues related to HR1892 "Bipartisan Budget Act of 2018"; issues related to National Institute of Health (NIH) funding; and issues related to Biomedical Advanced Research and Development Authority (BARDA)".
Bipartisan Budget Act of 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Biomedical Advanced Research and Development Authority (BARDA)" funding;and issues related to HR1892 "Bipartisan Budget Act of 2018.
Bipartisan Budget Act of 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Biomedical Advanced Research and Development Authority (BARDA)" funding;and Part D and other issues related to HR1892 "Bipartisan Budget Act of 2018.
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related to Pandemic and All Hazards Preparedness (PAHPA)reauthorization; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to Right to Try; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to FDA User Fee Reauthorization; issues related to HR2212 "CREATES Act of 2017"; and issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017".
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related H.R. 6378 "Pandemic and All Hazards Preparedness (PAHPA)Advancing Innovation Act"; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to HR2212 "CREATES Act of 2017";issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017"; issues related S. 2852 "Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) of 2018"; issues related to PAHPA reauthorization; and issues related to S.2465 "Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018"
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related H.R. 6378 "Pandemic and All Hazards Preparedness (PAHPA)Advancing Innovation Act"; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to HR2212 "CREATES Act of 2017";issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017"; issues related to Medicare rebate disclosure; issues related to S. 2852 "Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018"; issues related to S. 297 "Increasing Competition in Pharmaceuticals Act"; and issues related to S.2465 "Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018"
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related H.R. 6378 "Pandemic and All Hazards Preparedness (PAHPA)Advancing Innovation Act"; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to HR2212 "CREATES Act of 2017";issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017"; issues related S. 2852 "Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) of 2018"; issues related to PAHPA reauthorization; and issues related to S.2465 "Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018"
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related H.R. 6378 "Pandemic and All Hazards Preparedness (PAHPA)Advancing Innovation Act"; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to HR2212 "CREATES Act of 2017";issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017"; issues related to Medicare rebate disclosure; issues related to S. 2852 "Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018"; issues related to S. 297 "Increasing Competition in Pharmaceuticals Act"; and issues related to S.2465 "Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018"
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related to Pandemic and All Hazards Preparedness (PAHPA)reauthorization; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to Right to Try; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to FDA User Fee Reauthorization; issues related to HR2212 "CREATES Act of 2017"; and issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017".
National Defense Authorization Act for Fiscal Year 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues with march-in rights within H.R 2810 National Defense Authorization Act for Fiscal Year 2018; issues related to Compulsory Licensing.
National Defense Authorization Act for Fiscal Year 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues with march-in rights within H.R 2810 National Defense Authorization Act for Fiscal Year 2018.
National Defense Authorization Act for Fiscal Year 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues with march-in rights within H.R 2810 National Defense Authorization Act for Fiscal Year 2018.
Vaccine Access Improvement Act of 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to H.R.4993 "Vaccine Access Improvement Act of 2018"; and issues related to Orphan Drug Tax Credit
Vaccine Access Improvement Act of 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Border adjustability tax; issues related to H.R.4993; issues related to H.R.4993 "Vaccine Access Improvement Act of 2018"; and issues related to Orphan Drug Tax Credit
Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related to Pandemic and All Hazards Preparedness (PAHPA)reauthorization; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to Right to Try; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to FDA User Fee Reauthorization; issues related to HR2212 "CREATES Act of 2017"; and issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017".
Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related H.R. 6378 "Pandemic and All Hazards Preparedness (PAHPA)Advancing Innovation Act"; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to HR2212 "CREATES Act of 2017";issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017"; issues related to Medicare rebate disclosure; issues related to S. 2852 "Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018"; issues related to S. 297 "Increasing Competition in Pharmaceuticals Act"; and issues related to S.2465 "Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018"
Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related H.R. 6378 "Pandemic and All Hazards Preparedness (PAHPA)Advancing Innovation Act"; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to HR2212 "CREATES Act of 2017";issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017"; issues related S. 2852 "Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) of 2018"; issues related to PAHPA reauthorization; and issues related to S.2465 "Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018"
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related H.R. 6378 "Pandemic and All Hazards Preparedness (PAHPA)Advancing Innovation Act"; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to HR2212 "CREATES Act of 2017";issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017"; issues related to Medicare rebate disclosure; issues related to S. 2852 "Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018"; issues related to S. 297 "Increasing Competition in Pharmaceuticals Act"; and issues related to S.2465 "Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018"
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related H.R. 6378 "Pandemic and All Hazards Preparedness (PAHPA)Advancing Innovation Act"; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to HR2212 "CREATES Act of 2017";issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017"; issues related S. 2852 "Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) of 2018"; issues related to PAHPA reauthorization; and issues related to S.2465 "Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018"
Over-the-Counter Drug Safety, Innovation, and Reform Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related H.R. 6378 "Pandemic and All Hazards Preparedness (PAHPA)Advancing Innovation Act"; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to HR2212 "CREATES Act of 2017";issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017"; issues related to Medicare rebate disclosure; issues related to S. 2852 "Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018"; issues related to S. 297 "Increasing Competition in Pharmaceuticals Act"; and issues related to S.2465 "Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018"
Over-the-Counter Drug Safety, Innovation, and Reform Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related to Pandemic and All Hazards Preparedness (PAHPA)reauthorization; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to Right to Try; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to FDA User Fee Reauthorization; issues related to HR2212 "CREATES Act of 2017"; and issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017".
Over-the-Counter Drug Safety, Innovation, and Reform Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related H.R. 6378 "Pandemic and All Hazards Preparedness (PAHPA)Advancing Innovation Act"; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to HR2212 "CREATES Act of 2017";issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017"; issues related S. 2852 "Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) of 2018"; issues related to PAHPA reauthorization; and issues related to S.2465 "Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018"
Over-the-Counter Drug Safety, Innovation, and Reform Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing; and issues related to Pandemic and All Hazards Preparedness (PAHPA)reauthorization; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to Right to Try.
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related H.R. 6378 "Pandemic and All Hazards Preparedness (PAHPA)Advancing Innovation Act"; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to HR2212 "CREATES Act of 2017";issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017"; issues related to Medicare rebate disclosure; issues related to S. 2852 "Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018"; issues related to S. 297 "Increasing Competition in Pharmaceuticals Act"; and issues related to S.2465 "Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018"
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related H.R. 6378 "Pandemic and All Hazards Preparedness (PAHPA)Advancing Innovation Act"; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to HR2212 "CREATES Act of 2017";issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017"; issues related S. 2852 "Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) of 2018"; issues related to PAHPA reauthorization; and issues related to S.2465 "Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018"
Protecting Medicare from Executive Action Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to repealing IPAB in S.251 "Protecting Medicare from Executive Action Act of 2017"; and issues related to the repeal of Non-Interference in Medicare Part D.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related H.R. 6378 "Pandemic and All Hazards Preparedness (PAHPA)Advancing Innovation Act"; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to HR2212 "CREATES Act of 2017";issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017"; issues related to Medicare rebate disclosure; issues related to S. 2852 "Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018"; issues related to S. 297 "Increasing Competition in Pharmaceuticals Act"; and issues related to S.2465 "Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018"
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related H.R. 6378 "Pandemic and All Hazards Preparedness (PAHPA)Advancing Innovation Act"; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to HR2212 "CREATES Act of 2017";issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017"; issues related S. 2852 "Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) of 2018"; issues related to PAHPA reauthorization; and issues related to S.2465 "Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018"
Increasing Competition in Pharmaceuticals Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related H.R. 6378 "Pandemic and All Hazards Preparedness (PAHPA)Advancing Innovation Act"; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to HR2212 "CREATES Act of 2017";issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017"; issues related to Medicare rebate disclosure; issues related to S. 2852 "Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018"; issues related to S. 297 "Increasing Competition in Pharmaceuticals Act"; and issues related to S.2465 "Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018"
Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act.
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to interest deductibility; issues related to stock attribution; issues related H.R. 1-Tax Cuts and Jobs Act; and issues related to foreign direct investment.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
Affordable and Safe Prescription Drug Importation Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, Section 202 Tropical disease product application; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 469 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to insulin pricing; general issues related to drug pricing and general issues related to Vaccine safety.
Affordable and Safe Prescription Drug Importation Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Safe and Affordable Drugs from Canada Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Drug Diversion and Counterfeit Crackdown Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to patent reform; H.R. 2376 Drug Diversion and Counterfeit Crackdown Act of 2017 to increase penalties for drug diversion.
FDA Reauthorization Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
FDA Reauthorization Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
National Defense Authorization Act for Fiscal Year 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to international intellectual property; provision ISI committee report language, amendments and march-in rights within S. 1519 National Defense Authorization Act for Fiscal Year 2018 and provision ISI committee report language, amendments and march-in rights within H.R. 2810 National Defense Authorization Act for Fiscal Year 201.
National Defense Authorization Act for Fiscal Year 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues with march-in rights within H.R 2810 National Defense Authorization Act for Fiscal Year 2018.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Restoring Access to Medication Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
H.R. 394 Restoring Access to Medication Act of 2017, provision to amend tax code to repeal ACA provisions disqualifying expenses for over-the-counter medications; S.85 Restoring Access to Medication Act of 2017, provision to amend tax code to repeal ACA provisions disqualifying expenses for over-the-counter medications.
Restoring Access to Medication Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to border adjustability tax; issues related to interest deductibility; issues related to H.R. 394 Restoring Access to Medication Act of 2017' issues related to S. 85 Restoring Access to Medication Act of 2017
Lower Drug Costs through Competition Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Lower Drug Costs through Competition Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, Section 202 Tropical disease product application; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 469 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to insulin pricing; general issues related to drug pricing and general issues related to Vaccine safety.
Protecting Seniors Access to Medicare Act
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the repeal of Non-Interference in Part D; H.R. 849, Protecting Seniors' Access to Medicare Act of 2017 to repeal provisions of the Affordable Care Act for IPAB; S. 251 Protecting Medicare from Executive Action Act of 2017 to repeal IPAB; S.260 Protecting Seniors' Access to Medicare Act of 2017 to repeal IPAB;
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Fair Accountability and Innovative Research Drug Pricing Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
National Defense Authorization Act for Fiscal Year 2018
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
General issues related to international intellectual property; provision ISI committee report language, amendments and march-in rights within S. 1519 National Defense Authorization Act for Fiscal Year 2018 and provision ISI committee report language, amendments and march-in rights within H.R. 2810 National Defense Authorization Act for Fiscal Year 201.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
Protecting Medicare from Executive Action Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the repeal of Non-Interference in Part D; H.R. 849, Protecting Seniors' Access to Medicare Act of 2017 to repeal provisions of the Affordable Care Act for IPAB; S. 251 Protecting Medicare from Executive Action Act of 2017 to repeal IPAB; S.260 Protecting Seniors' Access to Medicare Act of 2017 to repeal IPAB;
Protecting Seniors' Access to Medicare Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the repeal of Non-Interference in Part D; H.R. 849, Protecting Seniors' Access to Medicare Act of 2017 to repeal provisions of the Affordable Care Act for IPAB; S. 251 Protecting Medicare from Executive Action Act of 2017 to repeal IPAB; S.260 Protecting Seniors' Access to Medicare Act of 2017 to repeal IPAB;
Protecting Seniors' Access to Medicare Act of 2017
Client: SANOFI US SERVICES INC · Firm: SANOFI US SERVICES INC.
Issues related to the repeal of Non-Interference in Part D; general issues related to S.260 "Protecting Seniors' Access to Medicare Act of 2017".
Issues related to Buy America Executive Order.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2020 · third_quarter · Q3
Issues related to foreign supply chain; and general issues related to supply chain.
Issues related to Buy America Executive Order.
Issues related to Coronavirus- COVID-19; issues related to Influenza Vaccines; issues related to prescription medicines switch to over-the-counter; and other general issues related to routine influenza rates; issues related to 340B; issues related to cosmetic regulations; issues related to drug importation, issues related to international reference pricing; issues related to Most Favored Nation Executive Order; issues related to OTC monograph reform; issues related to Executive Order on Flu Vaccines; issues related to CMMI Insulin demo; issues related to copay accumulators; and issues related to HR3. "Lower Drug Cost Now act of 2019".
Issues related to Medicare Part D; issues related to IPI model; and issues related to Medicaid AMPCAP.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2020 · second_quarter · Q2
Issues related to BARDA/Biodefense appropriations; and issues related to S.4049 NDAA for FY 2021.
Issues related to Buy/America Executive Order and other general issues related to foreign supply chain.
Issues related to Coronavirus- COVID-19; issues related to Influenza Vaccines; issues related to prescription medicines switch to over-the-counter; issues related to drug pricing; issues related to insulin pricing; issues related to CMMI insulin demo; issues related to copay accumulators; and Medicare administrative fees for vaccines and other general issues related to routine immunizations.
Issues related to Medicare Part D; and issues related to home infusions of Part B medicines.
Issues related to Tax Reform; and issues related to Tax impact on supply chain.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2020 · first_quarter · Q1
Issues related to Foreign Supply Chain
Issues related to BARDA/Biodefense appropriations
Issues related to Tax Reform; and issues S.1654- Vaccine Access Improvement Act of 2019.
general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform in CARES Act; issues related to HSA/FSA in CARES Act; issues related to Vaccine provisions in CARES Act; issues related to prescription to over-the-counter switch; issues related to Drug Importation;issues related to H.R. 3 "Lower Drug Costs Now Act of 2019"; issues related to S. 2740 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019"; issues related to influenza vaccines; issues related to the Executive Order on Flu; issues related to Coronavirus COVID-19; issues related to Copay Accumulators; issues related to RSV access; issues related to HR.3433- Over the counter Monograph Safety, Innovation and Reform Act 2019; issues related to S.2158- Newborn Screening Saves Lives; and issues related to CMMI- Insulin Demo.
Issues related to Buy American Executive Order.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2019 · fourth_quarter · Q4
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to prescription to over-the-counter switch; issues related to compulsory licensing; issues related to Drug Importation;issues related to H.R. 3 "Lower Drug Costs Now Act of 2019"; issues related to S. 2740 "Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019"; issues related to influenza vaccines; issues related to the Executive Order on Flu; and issues related to H.R. 19 "Lower Costs, More Cures Act of 2019" .
Issues related to blended ASP authorized generics; issues related to Medicaid AMP CAP; issues related to S.99 "Medicare Drug Price Negotiation Act"; and issues related to Medicare Part D.
Issues related to USMCA- United States- Mexico-Canada Agreement.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2019 · third_quarter · Q3
Issues related to Compulsory Licensing; issues related to drug patents; and issues related to S. 2082 "Support Technology and Research for Our Nation's Growth and Economic Resilience Patents Act of 2019".
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to Arbitration;; issues related to S.1379 " Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019"; issues related to H.R. 269 "Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019; issues related to prescription to over-the-counter switch; issues related to compulsory licensing; issues related to Drug Importation; and issues related to H.R. 3 "Lower Drug Costs Now Act of 2019".
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2019 · second_quarter · Q2
Issues related to Compulsory Licensing; issues related to drug patents; and issues related to S. 1416 "Affordable Prescription for Patients Act of 2019".
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing; issues related to seasonal influenza vaccination; issues related to Drug Importation;issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to OTC Monograph Reform; issues related to Arbitration; issues related to H.R. 2087 "Drug Price Transparency Act"; issues related to S.977 "Medicare Drug Price Negotiation Act"; issues related to S.1379 " Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019"; and issues related to H.R. 269 "Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019:.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2019 · first_quarter · Q1
Issues related to Compulsory Licensing; issues related to drug patents; and issues related to S.344 "Hatch-Waxman Integrity Act of 2019".
Issues related to the HHS Rebate rule; general issues related to drug pricing; issues related to cosmetic regulations; issues related to insulin pricing; issues related to seasonal influenza vaccination; issues related to Drug Importation; issues related to S. 97 " Affordable and Safe Prescription Drug Importation Act"; issues related to s.102 "Prescription Drug Price Relief Act of 2019"; issues related to International Reference pricing; issues related to dietary supplements; and issues related to H.R. 269 "Pandemic and All Hazards Preparedness and Advancing Innovation Act of 2019:.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2018 · fourth_quarter · Q4
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related H.R. 6378 "Pandemic and All Hazards Preparedness (PAHPA)Advancing Innovation Act"; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to HR2212 "CREATES Act of 2017";issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017"; issues related S. 2852 "Pandemic and All-Hazards Preparedness and Advancing Innovation Act (PAHPA) of 2018"; issues related to PAHPA reauthorization; and issues related to S.2465 "Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018"
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2018 · third_quarter · Q3
Issues related to Biomedical Advanced Research and Development Authority (BARDA)" funding;and Part D and other issues related to HR1892 "Bipartisan Budget Act of 2018.
Issues related to Border adjustability tax; issues related to H.R.4993; issues related to H.R.4993 "Vaccine Access Improvement Act of 2018"; and issues related to Orphan Drug Tax Credit
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related H.R. 6378 "Pandemic and All Hazards Preparedness (PAHPA)Advancing Innovation Act"; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to HR2212 "CREATES Act of 2017";issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017"; issues related to Medicare rebate disclosure; issues related to S. 2852 "Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018"; issues related to S. 297 "Increasing Competition in Pharmaceuticals Act"; and issues related to S.2465 "Sickle Cell Disease and other Heritable Blood Disorders Research, Surveillance, Prevention and Treatment Act of 2018"
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2018 · second_quarter · Q2
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing;issues related to Pandemic and All Hazards Preparedness (PAHPA)reauthorization; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to Right to Try; issues related to 340B Reform; issues related to Drug Importation; issues related to vaccine safety;issues related to HR5333 "Over-the-Counter Monograph Safety, Innovation, and reform Act of 2018; issues related to FDA User Fee Reauthorization; issues related to HR2212 "CREATES Act of 2017"; and issues related to HR 2439 "Fair Accountability and Innovation Research Drug Act of 2017".
Issues related to the repeal and non-interference in Part D.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2018 · first_quarter · Q1
Issues related to repealing IPAB in S.251 "Protecting Medicare from Executive Action Act of 2017"; and issues related to the repeal of Non-Interference in Medicare Part D.
Issues related to S.2315 "Over-the-Counter Drug Safety, Innovation, and Reform Act; general issues related to drug pricing;issues related to cosmetic regulations; issues related to insulin pricing; and issues related to Pandemic and All Hazards Preparedness (PAHPA)reauthorization; issues related to Medicare Part D; issues related to flu and Veterans Affairs; issues related to seasonal influenza vaccination; issues related to Right to Try.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2017 · fourth_quarter · Q4
Issues related to interest deductibility; issues related to stock attribution; issues related H.R. 1-Tax Cuts and Jobs Act; and issues related to foreign direct investment.
Issues with march-in rights within H.R 2810 National Defense Authorization Act for Fiscal Year 2018.
Issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing;issues related to FDA approval of Follow-on Biologics; issues related to cosmetic regulations; issues related to insulin pricing; and issues related to Pandemic and All Hazards Preparedness (PAHPA).
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2017 · third_quarter · Q3
General issues related to international intellectual property; provision ISI committee report language, amendments and march-in rights within S. 1519 National Defense Authorization Act for Fiscal Year 2018 and provision ISI committee report language, amendments and march-in rights within H.R. 2810 National Defense Authorization Act for Fiscal Year 201.
Issues related Zika vaccine development; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency issues related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 2430 FDA Reauthorization Act of 201; and issues related to FDA approval of Follow-on Biologics.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2017 · second_quarter · Q2
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, ; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to drug pricing; issues related to S.183 Short on Competition Act; issues related to S.934 FDA Reauthorization Act of 2017; issues related to H.R. 2212 CREATES Act of 2017; issues related to H.R. 1231 RACE for Children Act; drug price transparency issues related to H.R. 2439 Fair Accountability and Innovative Research Drug Pricing Act of 2017; drug price transparency related to S. 1131 Fair Accountability and Innovative Research Drug Pricing Act of 2017; issues related to H.R. 1703Medical Product Communications Act of 2017; issues related to H.R. 1148 FAST Act of 2017; issues related to S. 456 RACE for Children Act; issues related to H.R. 2368 Right to Try Act; issues related to H.R. 1223 OPEN Act; issues related to H.R. 2430 FDA Reauthorization Act of 201; issues related to S. 204 Right to Try Act; issues related to H.R. 1480 Safe and Affordable Drugs from Canada Act of 2017; issues related to H.R. 3165 REVAMP Act of 2017 (draft); issues related to H.J. Res. 51 Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act; general issues related to the Food and Drug Administration User Fee Reauthorization
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2017 · first_quarter · Q1
Issues related to Affordable Care Act repeal and replace; health issues related Zika vaccine development; issues related to H.R. 749 Lower Cost Through Drug Competition Act, Section 202 Tropical disease product application; issues related to drug importation; issues related to H.R. 1245 Affordable and Safe Prescription Drug Importation Act; issues related to S. 469 Affordable and Safe Prescription Drug Importation Act; issues related to S. 64 Safe and Affordable Drugs from Canada Act of 2017; issues related to Over the Counter (OTC) Monograph reform; general issues related to insulin pricing; general issues related to drug pricing and general issues related to Vaccine safety.
General issues related to border adjustability tax; issues related to interest deductibility; issues related to H.R. 394 Restoring Access to Medication Act of 2017' issues related to S. 85 Restoring Access to Medication Act of 2017
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2016 · fourth_quarter · Q4
Provisions of S.31 "Medicare Prescription Drug Price Negotiation Act; issues related to Medicare Part B reimbursement; and issues related to Medicare Part D program
General issues related to the 340B Federal Drug Pricing Program.
Issues related to the Over The Counter (OTC) Monograph reform; general issues related to Zika Outbreaks; issues related to Center for Medicaid and Medicaid Services Innovation Center; Issues related to research and development innovation and education; general issues related to insulin pricing; general issues related to Tropical Disease PRV Program; general issues related to Vaccine Safety; issues related to Access to Adult Vaccines; issues related to H.R. 3299 Strengthening Public Health Emergency Response Act; importation issues related to S.122 Safe and Affordable Drugs from Canada Act of 2015; issues related to pricing and cost value; issues related to the Prescription Drug User Fee Act; and issues related to 21st Century Cures Initiative.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2016 · third_quarter · Q3
Issues related to the Over The Counter (OTC) Monograph reform; general issues related to Zika Outbreaks;general issues related to the value of prescription medicines; issues related to S. 3900 Amendment for Zika Response and Preparedness; issues related to H.R. 5243 "Zika Response Appropriations Act, 2016"; education and awareness of Dengue; issues related to the Independent Payment Advisory Board IPAB; issues related to Center for Medicaid and Medicaid Services Innovation Center; all issues related to the Innovation for Healthier Americans Initiative; Issues related to research and development innovation and education; general issues related to emerging infectious diseases; general issues related to counterfeit pharmaceuticals; issues related to H.R. 3678 "Preserving Access to Orphan Drug Act of 2015"; general issues related to importation; general issues related to insulin pricing; general issues related to priority review vouchers; and general issues related to Tropical Disease PRV Program.
Issues related to animal compounding.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2016 · second_quarter · Q2
General issues related to corporate tax reform, including the deduction of interest; all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"; issues related to Department of Treasury regulations on inversions.
General issues related to the 340B Federal Drug Pricing Progranm
General issues related to the Medicare Part D Program and government price setting; and provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; general issues related to Medicare Part B Reimbursement and Center for Medicaid and Medicare Innovation Part B rule
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2016 · first_quarter · Q1
Education and awareness of the 2015-2016 influenza season; all issues related to the Innovations for Healthier Americans Initiative; general issues related to the value of prescription medicines; general issues related to the importation of prescription drugs including all progvisions of S122 "Safe and Affordable Drugs from Canada Act of 2015"; issues related to the Over The Counter (OTC) Monograph reform; and general issues related to access to adult vaccines; general issues related to Zika Outbreaks; general issues related to Priority Review Vouchers; general issues related to Tropical Disease PRV Program; education and awareness of pandemic and biodefense funding; general issues related to the value of prescription medicines; issues related to S2742 "Promoting Biomedical Research and Public Health Patient Act" provision Section 6 National Vaccine Injury; issues related to S2512/H.R. "Adding Zika Virus to the FDA Priority Review Voucher Program Act"
General issues related to corporate tax reform, including the deduction of interest,general issues related to the 40% excise tax on employer-sponsored health care; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015".
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2015 · fourth_quarter · Q4
Education and awareness of the 2015-2016 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all issues related to the Innovations for Healthier Americans Initiative and the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; all provisions of Preserving Access to Orphan Drugs Act (discussion draft), HR3678 "Preserving Access to Orphan Drugs Act" and HR3618 "Orphan Drug Fairness Act"; education and awareness of diabetes and related treatments; education about our new cholesterol lowering drug and policy issues related to cardiovascular disease; issues related to barriers to the export of domestically manufactured vaccines; general issues related to the value of prescription medicines; general issues related to the importation of prescription drugs including all progvisions of S122 "Safe and Affordable Drugs from Canada Act of 2015"; issues related to the Over The Counter (OTC) Monograph reform; and general issues related to access to adult vaccines.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2015 · third_quarter · Q3
Issues related to the Medicaid rebate policy; general issues related to the Mediare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; and general issues related to chronic care reform in the Medicare program.
General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2015 · second_quarter · 2A
Issues related to the Medicaid rebate policy; general issues related to the Mediare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; proposals set forth in the President's Budget Request related to restructuring copayments for generic and brand drugs for low income beneficiaries; reducing reimbursement for Medicare Part B medicines; all provisions of HR2 "Medicare Access and CHIP Reauthorization Act of 2015"; all provisions of HR2005 and S1083 "Medicare Drug Savings Act of 2015" and general issues related to chronic care reform in the Medicare program.
Education and awareness of the 2014-2015 influenza season; education and awareness of Avian influenza; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of S320 and HR744 "Medical Innovation Act"; the importance of immunizations for herd immunity; all issues related to the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; general issues related to the importation of pharmaceutical products, including all provisions of S122 "Safe and Affordable Drugs from Canada Act of 2015; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); The President's Budget Proposal - the proposal related to reducing from 12 years to 7 years the data exclusivity period for innovator biologics and the proposal related to generating additional savings from the Independent Payment Advisory Board (IPAB); education and awareness of diabetes and related treatments; issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis; and education and awareness of cardiovascular disease and related treatments.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2015 · second_quarter · Q2
General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.
International intellectual property issues; general issues related to patent settlements; and all provisions of HR9 "The Innovation Act" and S1137 "Protecting American Talent and Entrepreneurship Act of 2015"
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2015 · first_quarter · Q1
Issues related to the Medicaid rebate policy; general issues related to the Medicare Part D program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; general issues related to the Medicare Part B reimbursement of prescription drugs; proposals set forth in the President's Budget Request relating to applying a Medicaid rebate to Medicare Part D for low income subsidy beneficiaries, increasing the manufacturer Part D coverage gap discounts for brand name drugs, repealing the non-interference provision, restructuring generic and brand copayments for low income subsidy beneficiaries, and reducing reimbursement for Medicare Part B medicines; and all provisions of HR2 "Medicare Access and CHIP Reauthorization Act of 2015"
Education and awareness of the 2014-2015 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of S320 and HR744 "Medical Innovation Act"; the importance of immunizations for herd immunity; all issues related to the 21st Century Cures Initiative; general issues related to the importation of pharmaceutical products, including all provisions of S122 "Safe and Affordable Drugs from Canada Act of 2015; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); The President's Budget Proposal - the proposal related to reducing from 12 years to 7 years the data exclusivity period for innovator biologics and the proposal related to generating additional savings from the Independent Payment Advisory Board (IPAB); education and awareness of diabetes and related treatments; OTC-HSA; general issues related to awareness of Ebola; and education and awareness of cardiovascular disease and related treatments.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2014 · third_quarter · 3A
Education and awareness of issues related to illegal compounding of veterinary drugs for animals; issues related to the veterinarian biologics National Environmental Policy Act (NEPA) exclusion.
Issues related to the Medicaid drug rebate policy; issues related to Medicare Part B Reimbursement of prescription drugs; issues related to Medication Therapy Management; and general issues related to the Medicare Part D Program.
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014"; continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; all provisions of HR351 and S351 "Protecting Seniors' Access to Medicare Act of 2013"; general issues related to health care reform; and all general issues related to the 21st Century Cures Initiative.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2014 · fourth_quarter · Q4
Issues related to the Medicaid drug rebate policy; issues related to Medicare Part B Reimbursement of prescription drugs; and general issues related to the Medicare Part D Program
Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014", S2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 or the COMPETE Act of 2014, and in S2260 "Expiring Provisions Improvement, Reform, andEfficiency Act of 2014 (or EXPIRE Act of 2014); tax policy issues related to corporate inversions including S2786 "Corporate Inverters Earnings Stripping Reform Act of 2014" and HR4679 & S2360 "Stop Corporate Inversions Act of 2014" and S2704 & HR5278 "No Federal Contracts for Corporate Deserters Act of 2014"; and all provisions of HR2835 and S 1647 "Restoring Access to Medication Act of 2013"
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2014 · third_quarter · Q3
Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014", HR 3474 "Hire More Heroes Act of 2014", and HR4 "Jobs for America Act"; S2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 orthe COMPETE Act of 2014; tax policy issues related to corporate inversions including S2786 " Corporate Inverters Earnings Stripping Reform Act of 2014" and HR4679 & S2360 "Stop Corporate Inversions Act of 2014" and S2704 & HR5278 "No Federal Contracts for Corporate Deserters Act of 2014"; and all provisions of HR2835 and S 1647 "Restoring Access to Medication Act of 2013"
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014"; continuedover-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; all provisions of HR351 and S351 "Protecting Seniors' Access to Medicare Act of 2013"; general issues related to health care reform; and all general issues related to the 21st Century Cures Initiative.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2014 · second_quarter · Q2
Education and awareness of issues related to illegal compounding of veterinary drugs for animals
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014"
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2014 · first_quarter · Q1
Corporate tax reform, including Chairman Camps discussion draft legislation Tax Reform Act of 2014; a strengthened and permanent U.S. R&D tax credit; and all provisions of HR 2835 and S1647 "Restoring Access to Medication Act of 2013"
Education and awareness regarding illegal compounding of veterinary drugs for animals
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; S1871 "Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Improvement Act of 2013"; and all provisions of HR1024 a "Medication Therapy Management Empowerment Act of 2013"; all provisions of HR3890 and S1932 "Better Care, Lower Cost Act"; issues related to thecontinued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; general issues related to FDA and NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; and awareness and education about Sanofi's Access to Medicines Program
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2013 · fourth_quarter · Q4
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of Dengue; general issues related to NIH funding; all provisions of HR 2094 "School Access to Emergency Epinephrine Act"; all provisions of HR2985 "The Combination Drug Development Incentive Act"; S1871 "Sustainable Growth Rate (SGR) Repeal and Medicare Beneficiary Access Improvement Act of2013"; and all provisions of HR1024 and S557 "Medication Therapy Management Empowerment Act of 2013"
Education and awareness regarding illegal compounding of veterinary drugs for animals and general issues related to animal vaccine lot release.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2013 · third_quarter · Q3
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding, including policy ramifications of recent BARDA contract awards; education and awareness of dengue; general issues related to FDA funding; general issues related to NIH funding; general issues related to diabetes awareness; all provisions of HR 2094 "School Access to Emergency Epinephrine Act"; and issues related to the continued over-the-counter availability of allergy, cough and coldmedicines that contain pseudoephedrine
Issues related to coverage and reimbursement for those who are covered by the Medicaid program and the Medicare program, including the Part D prescription drug benefit; general issues related to reform of the Medicare Part D program; and issues related to the Medicare Part B reimbursement of prescription drugs.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2013 · second_quarter · 2A
Education and awareness of issues related to the compounding of medications for animal health, including all provisions of S 959 "Pharmaceutical Compounding Quality and Accountability Act"; all provisions of HR 1407 "Animal Drug User Fee Amendments of 2013" Education and awareness regarding illegal compounding of veterinary drugs for animals; all provisions of S 622 "Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013"
All provisions of HR 1919 "Safeguarding America's Pharmaceutical SAct of 2013" and all provisions of S 957 "Drug Supply Chain Security Act"
Issues related to changes to the Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement for those who are covered by the Medicaid program and the Medicare program, including the Part D prescription drug benefit; and general issues related to the Medicare Part D program.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2013 · second_quarter · Q2
All provisions of HR 1919 "Safeguarding America's Pharmaceutical SAct of 2013" and all provisions of S 957 "Drug Supply Chain Security Act"
Education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of dengue; FDA funding; NIH funding; general issues related to diabetes awareness; all provisions of S 557 "Medication Therapy Management Empowerment Act of 2013"; all provisions of S 596 "Fostering Independence Through Technology Act of 2013"; issues related to the Independent Payment Advisory Board; general issues related to School Access to EmergencyEpinephrine; and issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2013 · first_quarter · 1A
S. 77 "Prescription Drug and Health Improvement Act of 2013" - all provisions; S117, "Medicare Prescription Drug Price Negotiation Act of 2013" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of dengue; FDA funding; reauthorization of Pandemic and All HazardsPreparation Act; general issues related to the importation of pharmaceutical products; issues related to chronic disease treatment adherence with the CMS Innovation Center; general issues related to School Access to Emergency Ephinephrine; and issues related to the data exclusivity period for generic biologics.
Education and awareness regarding illegal compounding of veterinary drugs for animals; general issues related to the reauthorization of the Animal Drug User Fee Act; HR1150 "Preservation of Antibiotics for Medical Treatment Act of 2013"; HR820 "Delivering Antimicrobial Transparency in Animals Act of 2013."
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2013 · first_quarter · Q1
Education and awareness regarding illegal compounding of veterinary drugs for animals; general issues related to the reauthorization of the Animal Drug User Fee Act; HR1150 "Preservation of Antibiotics for Medical Treatment Act of 2013"; HR820 "Delivering Antimicrobial Transparency in Animals Act of 2013."
S. 77 "Prescription Drug and Health Improvement Act of 2013" - all provisions; S117, "Medicare Prescription Drug Price Negotiation Act of 2013" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of dengue; FDA funding; reauthorization of Pandemic and All HazardsPreparation Act; general issues related to the importation of pharmaceutical products; issues related to chronic disease treatment adherence with the CMS Innovation Center; general issues related to School Access to Emergency Ephinephrine; and issues related to the data exclusivity period for generic biologics.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2012 · fourth_quarter · 4A
S810 and HR1513 "Great Ape Protection and Cost Saving Act of 2011" - all provisions.
Extension of the U.S. R&D tax credit and all such provisions in HR942 "The American Research and Competitiveness Act of 2011" S1577 "Greater Research Opportunities With Tax Help Act (GROWTH Act)", and HR8"American Taxpayer Relief Act of 2012"; adding Quadrivalent influenza vaccine formulation to the Vaccine Injury Compensation Program including such provisions in HR6687 and S3716 "To amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza within the taxable vaccines.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2012 · third_quarter · 3A
S3239 and HR3798 "Egg Products Inspection Act Amendments of 2012" - all provisions; and issues related to a National Environmental Policy Act (NEPA) exclusion for veterinary biologics
General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including issues related to the Independent Payment Advisory Board, and efforts to repeal provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues relatedto diabetes and patient access to diabetes care; HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue; and all provisions of H. Res. 295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease."
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2012 · second_quarter · 2A
General issues related to prescription drug supply chain, including importation safety, foreign inspections, track and trace, and drug shortage, including related amendments to HR5651 "Food and Drug Administration Reform Act of 2012" and S3187 "Food and Drug Administration Safety and Innovation Act"
Reauthorization of the Prescription Drug User Fee Act (PDUFA) including potential amendments and all provisions of HR5651 "Food and Drug Administration Reform Act of 2012" and S3187 "Food and Drug Administration Safety and Innovation Act"
General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" and efforts to repeal PL111-148 provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; S1002 and HR4223"SAFE DOSES Act" - all provisions; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues;education and awareness of dengue.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2012 · fourth_quarter · Q4
Extension of the U.S. R&D tax credit and all such provisions in HR942 "The American Research and Competitiveness Act of 2011" S1577 "Greater Research Opportunities With Tax Help Act (GROWTH Act)", and HR8"American Taxpayer Relief Act of 2012"; adding Quadrivalent influenza vaccine formulation to the Vaccine Injury Compensation Program including such provisions in HR6687 and S3716 "To amend the Internal Revenue Code of 1986 to include vaccines against seasonal influenza within the taxable vaccines.
Issues related to changes to the Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement issues for those who are covered by the Medicaid program and the Medicare program, including the Part D prescription drug benefit.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2012 · third_quarter · Q3
S3239 and HR3798 "Egg Products Inspection Act Amendments of 2012" - all provisions; and issues related to a National Environmental Policy Act (NEPA) exclusion for veterinary biologics
General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including issues related to the Independent Payment Advisory Board, and efforts to repeal provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue; and all provisions of H. Res. 295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease."
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2012 · second_quarter · Q2
General issues related to prescription drug supply chain, including importation safety, foreign inspections, track and trace, and drug shortage including related amendments to HR5651 "Food and Drug Administration Reform Act of 2012" and S3187 "Food and Drug Administration Safety and Innovation Act"
General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" and efforts to repeal PL111-148 provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; S1002 and HR4223 "SAFE DOSES Act" - all provisions; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue.
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2012 · first_quarter · Q1
Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including the Independent Payment Advisory Board (IPAB); awareness & issues related to diabetes and patient access to diabetes care; general issues related to prescription drug safety; HR2529 "Restoring Access to Medication Act" - all provisions; HR2245 "Preserving Access to Life-Saving Medications Act of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of dengue; all provisions of S1002 "Safe Doses Act"; awareness & issues related to patient access to care for Dengue; and all provisions of draft legislation "Immunization Improvements Act of 2011."
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2011 · fourth_quarter · Q4
Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including the Independent Payment Advisory Board (IPAB); awareness & issues related to diabetes and patient access to diabetes care; awareness & issues related to patient access to atrial fibrillation care, including all provisions in HRes295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease"; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of dengue; general issues related to prescription drug safety and the importation of prescription drugs including amendment No. 769 to H.R. 2112 "Consolidated and Further Continuing Appropriations Act, 2012"; all provisions of S1002 "Safe Doses Act"; awareness & issues related to patient access to care for C. Difficile; awareness about the company's Access to Medicines Program; awareness & issues related to patient access to care for Dengue; and all provisions of draft legislation "Immunization Improvements Act of 2011."
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2011 · third_quarter · Q3
Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including all provisions of HR2529 "Restoring Access to Medication Act", the Medication Therapy Management Program, and the Independent Payment Advisory Board (IPAB); awareness and issues related to diabetes and patient access to diabetes care; awareness & issues related to patient access to atrial fibrillation care, including all provisions in HRes295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease", and S Res 243 "A resolution promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with the disease"; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; intellectual propterty issues in the WHO global pandemic vaccine allocation plans; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of dengue; general issues related to prescription drug safety and the importation of prescription drugs; and all provisions of S1002 "Safe Doses Act".
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2011 · second_quarter · Q2
Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including all provisions of HR605 and S312 "Patients' Freedom to Choose Act," the Medication Therapy Management Program, transitions of care, and the Independent Payment Advisory Board (IPAB); awareness and issues related to patient access to diabetes care; awareness & issues related to patient access to atrial fibrillation care, including all provisions in HRes295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease", issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; intellectual propterty issues in the WHO global pandemic vaccine allocation plans; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of the company's global Access to Medicines Program; education and awareness of dengue; issues related to the Section 317 Program for vaccines; general issues related to prescription drug safety; and all provisions of S1002 "Safe Doses Act".
SANOFI US SERVICES INC via SANOFI US SERVICES INC.
2011 · first_quarter · Q1
General discussions regarding the reauthorization of the Prescription Drug User Fee Act (PDUFA)
Comparative effectiveness, including issues related to the Patient Centered Research Insitute, issues related to limitations on the use of Health Savings Accounts for over-the-counter medicines, repeal and defunding efforts, & general issues regarding implementation of HR3590 "The Patient Protection and Affordable Care Act" including the Medication Therapy Management Program transitions of care; awareness and issues related to patient access to diabetes care; awareness and issues related to patient access to atrial fibrillation care; all provisions of S668 "Health Care Bureaucrats Elimination Act" and HR452 "Medicare Decisions Accountability Act of 2011"; issues related to importation of prescription medicines; issues related to efforts to move pseudoephedrine products to prescription drug status; section 401 of S174 "Healthy Lifestyles and Prevention (HeLP) America Act"; and issues related to pandemic influenza and biodefense funding
Issues related to blended ASP authorized generics; issues related to Medicaid AMP CAP; issues related to international price index; and issues related to Medicare Part D.
Issues related to USMCA- United States- Mexico-Canada Agreement.
Filing targets: Administration for Children & Families (ACF), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
S.1089 "Restoring Access to Medication Act of 2019" provision to repeal tax provisions to prevent HSA eligibility for OTC medicines.
Issues related to S.340 "CREATES Act of 2019"; and issues related to HR 3199 "Terminating the Extension of Rights Misappropriated Act of 2019"
Issues related to S.99 "Medicare Drug Price Negotiation Act"; issues related to blended ASP authorized generics; issues related to Medicaid AMP CAP; and issues related to international price index.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to S.340 "CREATES Act of 2019".
Issues related to S.99 "Medicare Drug Price Negotiation Act"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to H.R.4993 "Vaccine Access Improvement Act of 2018"; and issues related to Orphan Drug Tax Credit
Issues related to Patent Reform.
Issues related to Compulsory Licensing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE
Issues with march-in rights within H.R 2810 National Defense Authorization Act for Fiscal Year 2018; issues related to Compulsory Licensing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Biomedical Advanced Research and Development Authority (BARDA)" funding;and issues related to HR1892 "Bipartisan Budget Act of 2018.
Issues with march-in rights within H.R 2810 National Defense Authorization Act for Fiscal Year 2018.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to HR1625 "Consolidated Appropriations Act of 2018"; issues related to HR1892 "Bipartisan Budget Act of 2018"; issues related to National Institute of Health (NIH) funding; and issues related to Biomedical Advanced Research and Development Authority (BARDA)".
Issues with march-in rights within H.R 2810 National Defense Authorization Act for Fiscal Year 2018.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 394 Restoring Access to Medication Act of 2017, provision to amend tax code to repeal ACA provisions disqualifying expenses for over-the-counter medications; S.85 Restoring Access to Medication Act of 2017, provision to amend tax code to repeal ACA provisions disqualifying expenses for over-the-counter medications.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
General issues related to patent reform; H.R. 2376 Drug Diversion and Counterfeit Crackdown Act of 2017 to increase penalties for drug diversion.
Issues related to the repeal of Non-Interference in Part D; H.R. 849, Protecting Seniors' Access to Medicare Act of 2017 to repeal provisions of the Affordable Care Act for IPAB; S. 251 Protecting Medicare from Executive Action Act of 2017 to repeal IPAB; S.260 Protecting Seniors' Access to Medicare Act of 2017 to repeal IPAB;
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the repeal of Non-Interference in Part D; general issues related to S.260 "Protecting Seniors' Access to Medicare Act of 2017".
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
All provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"; issues related to Corporate Tax Reform; and issues related to Department of Treasury regulations on inversions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
All provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"; issues related to Department of Treasury regulations on inversions.
Provisions of S31 "Medicare Prescription Drug Price Negotiation Act.
General issues related to the 340B Federal Drug Pricing Program.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, White House Office
Issues related to the Over The Counter (OTC) Monograph reform; and general issues related to access to adult vaccines; general issues related to Zika Outbreaks; general issues related to Tropical Disease PRV Program;general issues related to the value of prescription medicines and Japanese Biennial Pricing Review; issues related to S2512/H.R.4400 "Adding Zika Virus to the FDA Priority Review Voucher Program Act"; issues related to vaccine reimbursement; issues related to H.R. 3299 "Strengthening Public Health Emergency Response Act"; issues related to S. 3900 Amendment for Zika Response and Preparedness; issues related to H.R. 5243 "Zika Response Appropriations Act, 2016"; issues related to H.R. 5122 To prohibit further action on the proposed rule regarding testing of Medicare Part B prescription drug models; education and awareness of Dengue; issues related to the Independent Payment Advisory Board IPAB; issues related to Center for Medicaid and Medicaid Services Innovation Center; all issues related to the Innovation for Healthier Americans Initiative.
Issues related to veterinary biologics National Environmental Policy Act (NEPA)exclusion; Issues related to animal compounding.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Intl Trade Administration (ITA), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
General issues related to animal drug compounding; general issues related to the veterinary biologics National Environmental Policy Act (NEPA) exclusion.
Education and awareness related to Atopic dermatitis awareness
General issues related to reforms to the Vaccine Injury Compensation Program (VICP).
General issues related to the 340B Federal Drug Pricing Progranm
General issues related to the Medicare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; general issues related to Medicare Part B Reimbursement; general issues related to Medicare Chronic Care Reform
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS)
Education and awareness of issues related to illegal compounding of veterinary drugs for animals; and issues related to the veterinary biologics National Environmental Policy Act (NEPA) exclusion.
Issues related to the Medicaid prescription drug rebate program policy; general issues related to the Medicare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act".
General issues related to the 340B Federal Drug Pricing Program
General issues related to corporate tax reform, including the deduction of interest, an extension of bonus depreciation, a delay of the medical device tax, and a strengthened, permanent U.S. R&D tax credit, including all provisions of HR880 "American Research and Competitiveness Act of 2015"; and proposed amendment #2 to the Senate amendment to HR 2029, Rules Committee Print 114-40, showing the text of "Protecting Americans from Tax Hikes Act of 2015"; general issues related to the 40% excise tax on employer-sponsored health care, including all provisions of S2045 and HR2050 "Middle Class Health Benefits Tax Repeal Act", all provisions of HR879 "Ax the Tax on Middle Class Americans' Health Plans Act", and proposed amendment #1 to the Senate amendment to HR2029, Rules Committee Print 114-39, showing the text of the "Consolidated Appropriations Act, 2016"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015".
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
International intellectual property issues; general issues related to patent settlements; and all provisions of HR9 "The Innovation Act" and S1137 "Protecting American Talent and Entrepreneurship Act of 2015"
Education and awareness of the 2014-2015 influenza season; education and awareness of Avian influenza; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all issues related to the Innovations for Healthier Americans Initiative and the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); education and awareness of diabetes and related treatments; education about our new cholesterol lowering drug and policy issues related to cardiovascular disease; issues related to barriers to the export of domestically manufactured vaccines; general issues related to the value of prescription medicines; issues related to the Over The Counter (OTC) Monograph reform; general issues related to access to adult vaccines; and all provisions of S1972 "Airline Access to Emergency Epinephrine Act of 2015.".
General issues related to the 340B Federal Drug Pricing Program
Issues related to corporate tax reform, including the deduction of interest and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"; general issues related to the 40% excise tax on employer-sponsored health care, including all provisions of S2045 and HR2050 "Middle Class Health Benefits Tax Repeal Act" and all provisions of HR879 "Ax the Tax on Middle Class Americans' Health Plans Act"
Education and awareness of issues related to illegal compounding of veterinary drugs for animals; issues related to the veterinary biologics National Environmental Policy Act (NEPA) exclusion; and all provisions of HR3174 and S1200 "Fairness to Pet Owners Act of 2015."
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to Trade Promotion Authority (TPA) including all such provisions of S995 and HR1890 "Bipartisan Congressional Trade Priorities and Accountability Act of 2015" and HR1314 "Ensuring Tax Exempt Organizations the Right to Appeal Act (or Trade Act of 2015)" and such portions of those bills as included in HR 2146 Defending Public Safety Employees Retirement Act and general issues related to the Trans-Pacific Partnership (TPP) and Transatlantic Trade and Investment Partnership (TTIP) negotiations.
International intellectual property issues; general issues related to patent settlements; and all provisions of HR9 "The Innovation Act" and S1137 "Protecting American Talent and Entrepreneurship Act of 2015"
Issues related to corporate tax reform, including the deduction of interest, the Orphan drug tax credit, and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"
Education and awareness of issues related to illegal compounding of veterinary drugs for animals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Education and awareness of issues related to illegal compounding of veterinary drugs for animals
Education and awareness of the 2014-2015 influenza season; education and awareness of Avian influenza; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of S320 and HR744 "Medical Innovation Act"; the importance of immunizations for herd immunity; all issues related to the 21st Century Cures Initiative including all provisions of HR6 "To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes (21st Century Cures Act)"; general issues related to the importation of pharmaceutical products, including all provisions of S122 "Safe and Affordable Drugs from Canada Act of 2015; all provisions of Preserving Access to Orphan Drugs Act (discussion draft); The President's Budget Proposal - the proposal related to reducing from 12 years to 7 years the data exclusivity period for innovator biologics and the proposal related to generating additional savings from the Independent Payment Advisory Board (IPAB); education and awareness of diabetes and related treatments; issues related to the need for research into clinical tools to diagnose and assess the severity of atopic dermatitis; and education and awareness of cardiovascular disease and related treatments.
Issues related to the Medicaid rebate policy; general issues related to the Mediare Part D Program; coverage and reimbursement for the Medicare Part D prescription drug benefit and all provisions of S31 "Medicare Prescription Drug Price Negotiation Act"; proposals set forth in the President's Budget Request related to restructuring copayments for generic and brand drugs for low income beneficiaries; reducing reimbursement for Medicare Part B medicines; all provisions of HR2 "Medicare Access and CHIP Reauthorization Act of 2015"; all provisions of HR2005 and S1083 "Medicare Drug Savings Act of 2015" and general issues related to chronic care reform in the Medicare program.
Issues related to corporate tax reform, including the deduction of interest, the Orphan drug tax credit, and a strengthened and permanent U.S. R&D tax credit, and all provisions of HR880 "American Research and Competitiveness Act of 2015"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Education and awareness about the Oral Rabies Vaccine Program
Corporate tax reform; a strengthened and permanent U.S. R&D tax credit, including all provisions of HR880 "American Research and Competitiveness Act of 2015"; and all provisions of HR1270 and S709 "Restoring Access to Medication Act of 2015"
International intellectual property issues; general issues related to patent settlements; and all provisions of HR9 "The Innovation Act"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Corporate tax reform; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014", HR 3474 "Hire More Heroes Act of 2014", and HR4 "Jobs for America Act"; S2715 "Competitiveness and Opportunity by Modernizing and Permanently Extending the Tax Credit for Experimentation Act of 2014 or the COMPETE Act of 2014; tax policy issues related to corporate inversions including S2786 " Corporate Inverters Earnings Stripping Reform Act of 2014" and HR4679 & S2360 "Stop Corporate Inversions Act of 2014" and S2704 & HR5278 "No Federal Contracts for Corporate Deserters Act of 2014"; and all provisions of HR2835 and S 1647 "Restoring Access to Medication Act of 2013"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Education and awareness of the 2013-2014 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of Dengue; general issues related to FDA and NIH funding; all provisions of HR 2985 "Combination Drug Development Incentive Act of 2013"; education and awareness of diabetes and related treatment; and all provisions of HR 4502 "Stop Meth Labs and Enhance Patient Access Act of 2014"; continued over-the-counter availability of allergy, cough and coldmedicines that contain pseudoephedrine; education and awareness of cardiovascular disease; all provisions of HR351 and S351 "Protecting Seniors' Access to Medicare Act of 2013"; issues related to health care reform; general issues related to awareness of Ebola; and all issues related to the 21st Century Cures Initiative.
Education and awareness of issues related to illegal compounding of veterinary drugs for animals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Education and awareness of issues related to illegal compounding of veterinary drugs for animals; issues related to the veterinarian biologics National Environmental Policy Act (NEPA) exclusion
Issues related to the Medicaid drug rebate policy; issues related to Medicare Part B Reimbursement of prescription drugs; issues related to Medication Therapy Management; and general issues related to the Medicare Part D Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Corporate tax reform, including Chairman Camp's discussion draft legislation "Tax Reform Act of 2014"; all provisions of HR 4718 "To amend the Internal Revenue Code of 1986 to modify and make permanent bonus depreciation"; and maintaining the orphan drug tax credit; a strengthened and permanent U.S. R&D tax credit, including all such provisions in HR 4438 "American Research and Competitiveness Act of 2014" and HR 3474 "Hire More Heroes Act of 2014"; and all provisions of HR2835 and S 1647 "RestoringAccess to Medication Act of 2013"
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
Issues related to the Medicaid rebate policy; coverage and reimbursement for the Medicare Part D prescription drug benefit and the Medicare Part D annual call letter; general issues related to reform of the Medicare Part D program; and issues related to the Medicare Part B reimbursement of prescription drugs.
All provisions of HR 2052 and S 1023 "Global Investment in American Jobs Act of 2013"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
All provisions of HR 3204 "Drug Quality and Security Act" and efforts to seek support for inclusion on the Department of Commerce Manufacturing Council
Issues related to corporate income tax reform; a strengthened and permanent U.S. R&D tax credit; extending and maintaining the orphan drug tax credit; and all provisions of HR 2835 and S1647 "Restoring Access to Medication Act of 2013"
Issues related to coverage and reimbursement for those who are covered by the Medicaid program and the Medicare program, including the Part D prescription drug benefit; general issues related to reform of the Medicare Part D program; and issues related to the Medicare Part B reimbursement of prescription drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Education and awareness of issues related to the compounding of medications for animal health, including all provisions of S 959 "Pharmaceutical Compounding Quality and Accountability Act"; and education and awareness regarding illegal compounding of veterinary drugs for animals.
All provisions of HR 2052 and S 1023 "Global Investment in American Jobs Act of 2013"
general issues related to corporate income tax reform; a strengthened and permanent U.S. R&D tax credit; extending and maintaining the orphan drug tax credit; all provisions of HR 2835 "Restoring Access to Medication Act of 2013"
All provisions of HR 3204 "Drug Quality and Security Act"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Education and awareness of the 2012-2013 influenza season; education and awareness of pandemic and biodefense funding; education and awareness of dengue; FDA funding; NIH funding; general issues related to diabetes awareness; all provisions of S 557 "Medication Therapy Management Empowerment Act of 2013"; all provisions of S 596 "Fostering Independence Through Technology Act of 2013"; issues related to the Independent Payment Advisory Board; general issues related to School Access to EmergencyEpinephrine; and issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Education and awareness of issues related to the compounding of medications for animal health, including all provisions of S 959 "Pharmaceutical Compounding Quality and Accountability Act"; all provisions of HR 1407 "Animal Drug User Fee Amendments of 2013" Education and awareness regarding illegal compounding of veterinary drugs for animals; all provisions of S 622 "Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013"
Issues related to changes to the Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement for those who are covered by the Medicaid program and the Medicare program, including the Part D prescription drug benefit; and general issues related to the Medicare Part D program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to a National Environmental Policy Act (NEPA) exclusion for veterinary biologics; and raising awareness regarding illegal compounding of veterinary drugs for animals
General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act including issues related to the Independent Payment Advisory Board; "HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation ActReauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of pandemic and biodefense funding in FY2012 and related international intellectual property issues; and education and awareness of dengue.
Issues related to changes to the Medicare Part B reimbursement of prescription drugs; issues related to coverage and reimbursement issues for those who are covered by the Medicaid program and the Medicare program, including the Part D prescription drug benefit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to a National Environmental Policy Act (NEPA) exclusion for veterinary biologics; and raising awareness regarding illegal compounding of veterinary drugs for animals
General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act including issues related to the Independent Payment Advisory Board; "HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of pandemic and biodefense funding in FY2012 and related international intellectual property issues; and education and awareness of dengue.
S810 and HR1513 "Great Ape Protection and Cost Saving Act of 2011" - all provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Reauthorization of the Prescription Drug User Fee Act (PDUFA) including potential amendments and all provisions of HR5651 "Food and Drug Administration Reform Act of 2012" and S3187 "Food and Drug Administration Safety and Innovation Act"
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
General issues related to drug supply chain, including import safety, foreign inspections, track and trace, and drug shortage.
Reauthorization of the Prescription Drug User Fee Act (PDUFA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to provider reimbursement for the administration of vaccines; issues related to changing reimbursement for physicians under the Medicare Part B program and general issues related to changes to the Medicare Part D program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to changing reimbursement for physicians the Medicare Part B program and general issues related to changes to the Medicare Part D program.
General discussions regarding the reauthorization of the Prescription Drug User Fee Act (PDUFA); and education and awareness of vaccine production and infrastructure needs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Extension of the U.S. R&D tax credit and all such provisions in HR942 "The American Research and Competitiveness Act of 2011"
General issues related to the Medicare Part D program
HR 1249 "America Invents Act" provisions related to first to file, inter parties review and supplemental re-examination; intellectual property provisions in the pending South Korea, Columbia and Panama Free Trade Agreements
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
S23 "America Invents Act" (formerly "Patent Reform Act of 2011"), provisions related to first to file, inter parties review and supplemental re-examination; intellectual property provisions in the pending South Korea, Columbia and Panama Free Trade Agreements
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE